Caninized Monoclonal Antibody Against Interleukin-31

31 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

650.0%

Death Rate

Active Ingredients

Caninized Monoclonal Antibody Against Interleukin-31

Administration Routes

UnknownParenteral

Species Affected

Dog 31

Most Affected Breeds

Shepherd Dog - German 5

Unknown 3

Retriever - Labrador 2

Bulldog - French 1

Beagle 1

Setter - Gordon 1

Dog (other) 1

Bulldog 1

Spitz - German Pomeranian 1

Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1

Most Reported Reactions

Vomiting 13

Diarrhoea 10

Lethargy (see also Central nervous system depression in 'Neurological') 7

Not eating 6

Panting 4

Lethargy (see also Central nervous system depression in Neurological) 4

Elevated serum alkaline phosphatase (SAP) 3

Reddening of the skin 2

Decreased appetite 2

Proteinuria 2

Urine abnormalities NOS 2

Uncomfortable 2

Outcome Breakdown

Outcome Unknown

14 (45.2%)

Recovered/Normal

12 (38.7%)

Ongoing

3 (9.7%)

Euthanized

2 (6.5%)

Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.